José Domínguez Escrig

Dr. José Luís Domínguez-Escrig graduated in Medicine and Surgery in July1994, in Valencia, Spain, continuing his postgraduate training in the UK. Having completed his BST obtained the Membership of the Royal College of Surgeons of England in 2001 and the Fellowship of the Royal College of Surgeons in Urology, FRSC(Urol) in 2009.

From 2004 to 2006 he performed his research at the prestigious Northern Institute for Cancer Research-Newcastle University, UK. On completion of his research project, he submitted the Thesis “Tyrosine Kinase and Farnesyltarnsferase Inhibitors: Potential Selective Tailored Therapeutics in Bladder Cancer” and was awarded the Degree of Doctor of Medicine in 2006.

He has published in several international peer reviewed Journals and he has reviewed articles for Actas Urol Esp, Arch. Esp Urol, BJU Int, Urol Oncology, Eur Urol Focus, EUROS and the Journal of Urology and has imparted several lectures and presented at international meetings including AACR, AUA, EAU, BAUS, SIU and AEU.

He returned to Spain in 2011 and he is currently working as a Consultant Urology Surgeon at the Fundación Instituto Valenciano de Oncología (I.V.O.) in Valencia, where he has been appointed as Clinical Lead for BCa and UTUC, combining his clinical work with an active involvement in translational research, participating as PI in several Clinical Trials in bladder and prostate cancer. His main interests are urothelial carcinoma (BCa and UTUC) as well as the evaluation and clinical development of novel focal therapies in Uro-oncology.

He is the current Secretary of the Executive Committee of the European Board of Urology. Systematic reviewer and Associated Member since 2015, he is from 2022 Panel Member of the EAU NMIBC and UTUC Guidelines and Secretary elect of the EBU. Since 2017 he is member of the CUETO Group.